Puma Biotech’s new cancer drug Nerlynx suffered a terrible quarter. What gives?

Puma Biotech's U.S. launch of Nerlynx didn’t seem to be going well. As management offered patient discontinuations as one of many explanations, which they said the company is working hard to improve, analysts remain on the fence.